Episodic ataxia type 6

Episodic ataxia type 6 (EA6) is an extremely rare neurological disorder characterized by recurrent episodes of ataxia (impaired coordination and balance) that occur intermittently. It is caused by mutations in the SLC1A3 gene, which encodes the excitatory amino acid transporter 2 (EAAT1), a glial glutamate transporter predominantly expressed in the cerebellum. This transporter plays a critical role in clearing glutamate from synapses, and its dysfunction leads to impaired cerebellar signaling. The condition primarily affects the nervous system, particularly the cerebellum, which controls movement coordination and balance. Clinical features include episodic attacks of ataxia that may be triggered by stress, fever, or physical exertion. Some patients may also experience seizures, migraine headaches, and alternating hemiplegia. Between episodes, neurological function may return to baseline, although some individuals can develop progressive cerebellar dysfunction over time. Additional features reported in some cases include nystagmus and dysarthria (slurred speech). Due to the extreme rarity of EA6, there is no established standard treatment. Management is largely supportive and symptomatic, focusing on avoiding known triggers and managing acute episodes. Acetazolamide, which has shown benefit in other forms of episodic ataxia, may be considered, though its efficacy in EA6 specifically has not been well established. Antiepileptic medications may be used if seizures are present. Genetic counseling is recommended for affected families.

Common questions about Episodic ataxia type 6